Work

Impact of cardiac sarcoidosis on health-related quality of life

Year: 2026

Type: article

Abstract: Background and Aims Cardiac sarcoidosis (CS) carries a poorer prognosis than other sarcoidosis subtypes, but its impact on health-related quality of life (HRQoL) remains insufficiently characterized. To assess HRQoL in CS compared with pulmonary sarcoidosis (PS) and Finnish population norms, and to examine the prognostic value of patient-reported outcomes. Methods and Results In this multicentre cohort, 240 CS patients from the MIDFIN registry and 65 PS patients completed the RAND-36 and fatigue severity scale (FSS). CS patients (median age 56 years; 75% women) had significantly lower physical functioning (PF) and role-physical (RP) scores than PS patients and age- and sex-standardized Finnish population norms (P < .001). Mental health domains did not differ significantly between CS and PS. Fatigue was comparable (FSS 4.2 vs 3.8; P = .149). Impairment was most pronounced in CS patients with reduced left ventricular ejection fraction and prior ventricular tachycardia/ventricular fibrillation or heart failure; those with preserved left ventricular ejection fraction and no adverse events had scores similar to PS. Over 36 months, 38 CS patients experienced composite adverse events (27 ventricular tachycardia/ventricular fibrillation, 7 deaths, 2 heart transplants, 1 left ventricular assist device, 1 pericardiocentesis for sarcoid pericarditis). In multivariable Cox regression, each 10-point decrement in PF (HR 1.16, 95% CI 1.02–1.32, P = .028) and RP (HR 1.14, 95% CI 1.04–1.25, P = .006) independently predicted adverse events, outperforming NYHA class, which lost independent prognostic significance when PF or RP was included in the model. Conclusions CS substantially impairs physical HRQoL, and lower PF and RP scores predict adverse outcomes beyond conventional risk markers, supporting integration of HRQoL assessment into routine CS risk stratification.

Source: European Heart Journal - Valvular and Structural Heart Disease

DOI: 10.1093/ehjvshd/xwag035